Advances in hypofractionated radiotherapy for prostate cancer
10.3760/cma.j.cn113030-20240716-00273
- VernacularTitle:前列腺癌大分割放疗研究进展
- Author:
Yuchen HAN
1
;
Ping TANG
1
;
Yueping LIU
1
Author Information
1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院放疗科，北京 100021
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Radiotherapy;
Hypofractionation;
Efficacy;
Toxicities
- From:
Chinese Journal of Radiation Oncology
2025;34(8):824-832
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer (PC) is one of the common malignant tumors among men, and its incidence has been increased in China across these years. Radiotherapy is the mainstay therapy for PC. Due to the special biological characteristics of PC and the development of precision radiotherapy technology, hypofractionated regimens of radiotherapy are progressing rapidly, which has been increasingly applied in clinical practice and extensively studied by more and more researchers. In this review, the biological mechanisms of hypofractionated regimens, related clinical research, and practical applications of hypofractionated radiotherapy (such as definitive radiotherapy, postoperative adjuvant / salvage radiotherapy, oligometastasis radiotherapy, and pelvic lymph node radiotherapy) were summarized and its efficacy and toxicity profiles were analyzed, aiming to provide reference for scientific promotion of short‐course, hypofractionated precision radiotherapy for PC in China.
